Kimberly M. Murphy - 19 Sep 2024 Form 4 Insider Report for ORAGENICS INC (OGEN)

Reporting relationship: Director
Issuer ticker: OGEN
Reported as of: 19 Sep 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Sep 2024, 21:15:44 UTC
Prior SEC filing: 10 Aug 2023
Source filing: View source filing
Reporting owner signature: /s/ Julio C. Esquivel as Attorney-in-Fact for Kimberly Murphy

Key filing fact

Kimberly M. Murphy filed Form 4 for ORAGENICS INC (OGEN) on 20 Sep 2024.

Key facts

This page summarizes Kimberly M. Murphy's Form 4 filing for ORAGENICS INC (OGEN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 20 Sep 2024, 21:15.

Change

Previous filing in this sequence was filed on 10 Aug 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OGEN transaction Derivative

Non-Employee Director Option (Right to Buy)

Award

Transaction value: $0
Shares: +27,083
Change %
Price: $0.000000
Shares after: 27,083
Date: 19 Sep 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 27,083
Exercise price: $0.4800
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant.